06/22/2026
74% of patients remained drop-free for at least 3 years after a single SLT treatment.
The LiGHT Trial changed how we think about first-line glaucoma therapy. Selective laser trabeculoplasty delivered superior IOP stability compared to drops — at a lower cost, with fewer adverse events, and less disease progression. The data is clear: laser first is a viable, evidence-based choice for patients with ocular hypertension and open angle glaucoma.
Featuring insights from Dr. Shoham-Hazon (.eye), glaucoma and cataract surgeon, Atlantic Canada.